About this trial
Rare tumors are understudied, yet have the potential to shed light on vast areas of cancer research. Ovarian sex cord-stromal tumors, rare tumors of childhood and young adulthood, have recently been found to be associated with a lung cancer of early childhood called pleuropulmonary blastoma (PPB). The cause of these ovarian tumors is unknown. DICER1 mutations are seen in the majority of children with PPB. Research shows DICER1 mutations are also seen in some patients with ovarian tumors. Like PPB, ovarian stromal tumors are highly curable when found in early stage; however, later forms of the disease are aggressive and often fatal. The International Ovarian Stromal Tumor Registry collects clinical and biologic data to understand why these tumors occur and how to treat them. Current work involves the study of the role of DICER1 and miRNA expression in ovarian stromal tumors. Understanding the clinical history, predisposing factors and DICER1 and miRNA expression in these ovarian tumors of childhood will lead to targeted screening and risk stratification for evidence-based treatment and biologically rational therapies. These efforts will improve the lives of children by increasing survival and reducing late effects.
The specific goals of the International Ovarian and Testicular Stromal Tumor Registry are:
1. to understand risk factors by studying age, pathologic subtype, histopathologic features, tumor invasiveness, degree of differentiation, presence of metastasis 2. to collect information on personal and family history in order to refine the clinical characteristics of patients and families with and without germline DICER1 mutations and other genetic predisposing factors 3. to determine whether there is a pattern of gene expression or DNA alterations that correlate with predisposition to ovarian tumors, biologic behavior and clinical outcome 4. to determine optimal screening regimens 5. to use clinical data obtained through the Registry to refine treatment algorithms 6. to establish a collection of annotated biology specimens (tumor tissue and germline DNA) for future research
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Previous or current diagnosis of an ovarian sex cord stromal including but not limited to: Sertoli-Leydig cell tumor, gynandroblastoma (now enrolling these patients on PPB/DICER1 Registry), juvenile granulosa cell tumor, Sertoli cell tumor, sex cord-stromal tumor with annular tubules or undifferentiated stromal tumor
Previous or current diagnosis of a testicular stromal tumor including but not limited to: juvenile granulosa cell tumor, Sertoli cell tumor, Leydig cell tumor or undifferentiated stromal tumor
Disqualifiers
Unable to provide informed consent/assent
Adult Granulosa cell tumor (unless otherwise specified by Medical Director)
Trial population
Prospectively or retrospectively diagnosed patients with ovarian or testicular stromal tumors or ovarian small cell carcinoma
Trial design
Other
Other
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
DICER1 mutations in ovarian and testicular stromal tumors
We will analyze germline DNA from patients with gonadal stromal tumors to determine the presence of DICER1 mutations. The tumor tissue will also be sequenced. mRNA and miRNA expression will be analyzed on tumor tissue. Results of the above will be correlated with clinical outcome.
Secondary outcomes
Clinical factors associated with outcome in ovarian and testicular stromal tumors
We will analyze the clinical records to determine which factors influence prognosis
Pathologic and Genetic Correlations
We will correlate the pathologic and genetic data with clinical data to describe factors associated with poor prognosis.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Children's Hospitals and Clinics of Minnesota
Lead sponsor
Children's National Research Institute
Collaborator
Dana-Farber Cancer Institute
Collaborator
Washington University School of Medicine
Collaborator
University of Texas Southwestern Medical Center
Collaborator
M.D. Anderson Cancer Center
Collaborator
Children's Hospital Colorado
Collaborator
Rutgers University
Collaborator
Massachusetts General Hospital
Collaborator
Klinikum Dortmund Wirbelsäulenchirurgie
Collaborator
ResourcePath, LLC
Collaborator
Allina Health System
Collaborator
Phoenix Children's Hospital
Collaborator
University of Cambridge
Collaborator